References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30
- American Society for Clinical Oncology. Laryngeal and hypopharyngeal cancer: Statistics Cancer.net. 2016. Available at: http://www.cancer.net/cancer-types/laryngeal-and-hypopharyngeal-cancer/statistics
- American Cancer Society. Breast cancer survival rates. 2017. Available at: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
- American Society for Clinical Oncology. Nasopharyngeal cancer: Statistics. 2017. Available at: http://www.cancer.net/cancer-types/nasopharyngeal-cancer/statistics
- American Society for Clinical Oncology. Nasal cavity and paranasal sinus cancer: Statistics. 2017. Available at: http://www.cancer.net/cancer-types/nasal-cavity-and-paranasal-sinus-cancer/statistics
- American Cancer Society. Endometrial cancer survival, by stage. 2017. Available at: https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html
- American Cancer Society. Survival rates for ovarian cancer, by stage. 2017. Available at: https://www.cancer.org/cancer/ovarian-cancer/detection-diagnosis-staging/survival-rates.html
- American Cancer Society. What are the survival rates for colorectal cancer, by stage? 2017. Available at: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
- American Cancer Society. Non-small cell lung cancer survival by stage. 2017. Available at: https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagnosis-staging/survival-rates.html
- MacConaill LE. Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 2013;31:1815-24
- Ogino S, Chan AT, Fuchs CS, et al. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411
- Ogino S, Nishihara R, VanderWeele TJ, et al. Review article: The role of molecular pathological epidemiology in the study of neoplastic and non-neoplastic diseases in the era of precision medicine. Epidemiology 2016;27:602-11
- Colussi D, Brandi G, Bazzoli F, et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 2013;14:16365-85
- Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013;13:745-58
- Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015;372:724-34
- Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97
- Camp ER, Ellis LM. CCR 20th Anniversary Commentary: RAS as a biomarker for EGFR—targeted therapy for colorectal cancer—from concept to practice. Clin Cancer Res 2015;21:3578-80
- Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
- Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500
- Haslem DS, Van Norman SB, Fulde G, et al. A retrospective analysis of precision medicine outcomes in patients with advanced cancer reveals improved progression-free survival without increased health care costs. J Oncol Pract 2016;13(2):e108-e119
- Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26
- Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84
- Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857-65
- Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19
- Engstrom PF, Bloom MG, Demetri GD, et al. NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw 2011;9(Suppl6):S1-S16
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
- Lech G, Slotwinski R, Slodkowski M, et al. Colorectal cancer tumour markers and biomarkers: recent therapeutic advances. World J Gastroenterol 2016;22:1745-55
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: head and neck. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
- Peng H, Guo R, Chen L, et al. Prognostic impact of plasma Epstein-Barr virus DNA in patients with nasopharyngeal carcinoma treated using intensity-modulated radiation therapy. Sci Rep 2016;6:22000
- Shen C, Kehl KL, Zhao B, et al. Utilization patterns and trends in epidermal growth factor receptor (EGFR) mutation testing among patients with newly diagnosed metastatic lung cancer. Clin Lung Cancer 2017;18:e233-e41
- Shinde R, Cao X, Kothari S. Biopsy procedures and molecular testing utilization and related costs in patients with metastatic lung cancer. J Manag Care Spec Pharm 2016;22:1194-203
- Enewold L, Thomas A. Real-world patterns of EGFR testing and treatment with erlotinib for non-small cell lung cancer in the United States. PLoS One 2016;11:e0156728
- Pan IW, Mallick R, Dhanda R, et al. Treatment patterns and outcomes in patients with non-squamous advanced non-small cell lung cancer receiving second-line treatment in a community-based oncology network. Lung cancer (Amsterdam, Netherlands) 2013;82:469-76
- MacLean E, Louder A, Saverno K, et al. Molecular testing patterns in metastatic non-small cell lung cancer. Am J Manag Care 2016;22:e60-7
- Barr RD, Feeny D, Furlong W. Economic evaluation of treatments for cancer in childhood. Eur J Cancer 2004;40:1335-45
- SEER Cancer Stat Facts. National Cancer Institute. 2017. Available at: https://seer.cancer.gov/statfacts/
- Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300
- Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30
- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
- Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29
- SEER*Explorer: An interactive website for SEER cancer statistics. Beta Version. Surveillance Research Program, National Cancer Institute. 2010-2014. Available at: https://seer.cancer.gov/explorer/
- United States Bureau of Labor Statistics. Consumer Price Index (CPI). 2015. Available at: https://www.bls.gov/cpi/
- Misra D, Seo PH, Cohen HJ. Aging and cancer. Clin Adv Hematol Oncol 2004;2:457-65
- Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist 2000;5:224-37
- Warren JL, Yabroff KR. Challenges and opportunities in measuring cancer recurrence in the United States. J Natl Cancer Inst 2015;107. pii: djv134
- Chen L, Berek J. Ovarian cancer diagnosis and staging. 2017. Available at: https://www.uptodate.com/contents/ovarian-cancer-diagnosis-and-staging-beyond-the-basics
- Appleby J, Devlin N, Parkin D. NICE’s cost effectiveness threshold. BMJ 2007;335:358-9
- Eccleston A, Bentley A, Dyer M, et al. A cost-effectiveness evaluation of germline BRCA1 and BRCA2 testing in UK women with ovarian cancer. Value Health 2017;20:567-76
- Romanus D, Cardarella S, Cutler D, et al. Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer. J Thorac Oncol 2015;10:586-94
- Ladabaum U, Wang G, Terdiman J, et al. Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 2011;155:69-79
- Forsman RW. Why is the laboratory an afterthought for managed care organizations? Clin Chem 1996;42:813-16
- Mayo Clinic Medical Laboratories. Test utilization and the clinical laboratory. 2012. Available at: http://www.mayomedicallaboratories.com/articles/comminique/2012/05.html
- Akhmetov I, Bubnov RV. Assessing value of innovative molecular diagnostic tests in the concept of predictive, preventive, and personalized medicine. EPMA J 2015;6:19
- Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23
- Carlson B. KRAS testing: optimizing cancer therapy. Biotechnol Healthc 2009;6:7-9
- Kuznar W. Updated NCCN guideline calls for EGFR mutations testing in all patients with NSCLC. Value Based Cancer Care 2017. Available at: http://jhoponline.com/top-issues/2017-issues/august-2017-vol-10-no-3/17233-updated-nccn-guidelines-for-neuroendocrine-tumors-and-carcinoid-syndrome-features-new-therapies
- Kreys ED, Koeller JM. Documenting the benefits and cost savings of a large multistate cancer pathway program from a payer's perspective. J Oncol Pract 2013;9:e241-7
- Merck & Co. Inc. Keytruda® (pembrolizumab) - highlights of prescribing information. 2017. Available at: https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf